Morgan Stanley’s Asterias Biotherapeutics Warrants AST.WS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q3
– Sell
-1,345
Closed -$1K – 6829
2017
Q2
$1K Sell
1,345
-305
-18% -$138 ﹤0.01% 6566
2017
Q1
$0 Buy
1,650
+304
+23% +$112 ﹤0.01% 6777
2016
Q4
$1K Sell
1,346
-4,329
-76% -$2.32K ﹤0.01% 6505
2016
Q3
$3K Sell
5,675
-223
-4% -$61 ﹤0.01% 6352
2016
Q2
$1K Buy
+5,898
New +$3.07K ﹤0.01% 6486

Morgan Stanley's AST.WS Position: Q3 2017 in Review

Morgan Stanley sold out of Asterias Biotherapeutics Warrants (AST.WS) in Q3 2017, closing a stake of 1,345 shares — an estimated $1K sold.

Morgan Stanley first reported a position in AST.WS in Q2 2016 and held it in 5 quarters. The position peaked at $3K in Q3 2016. 3 funds tracked by Wall St. Rank hold AST.WS as of Q3 2017.

  • Morgan Stanley reported no remaining Asterias Biotherapeutics Warrants position as of Q3 2017 after selling out during the quarter.
  • Morgan Stanley sold 1,345 Asterias Biotherapeutics Warrants shares in Q3 2017, an estimated $1K.
  • Morgan Stanley first reported a position in Asterias Biotherapeutics Warrants in Q2 2016 and held it in 5 quarters.
  • Morgan Stanley's Asterias Biotherapeutics Warrants position peaked at $3K in Q3 2016.
  • 3 funds tracked by Wall St. Rank held Asterias Biotherapeutics Warrants as of Q3 2017.

Based on Morgan Stanley's 13F filing for Q3 2017, filed 14 Nov 2017.